Zoetis Inc (ZTS) Stock AnalysisZTSZoetis Inc

Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including vaccines, anti-infectives, parasiticides, dermatology, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Zoetis Inc. is a good buy right now due to its current price of $74.81, which is significantly below the average analyst price target of $94. Additionally, the company has a solid gross margin of 71.64% and a forward P/E ratio of 11.99, indicating potential for future growth despite recent stock price declines. The main risk is the 40.59% year-to-date change, reflecting significant volatility.

21 analysts cover ZTS: 14 rate it Buy, 7 Hold and 0 Sell. The average price target is 154.20.